122 related articles for article (PubMed ID: 35118463)
1. GM-CSF Promotes Immune Response and Survival in a Mouse Model of COVID-19.
Kendall LV; Boyd TD; Sillau SH; Bosco-Lauth A; Markham N; Fong D; Clarke P; Tyler KL; Potter H
Res Sq; 2022 Jan; ():. PubMed ID: 35118463
[TBL] [Abstract][Full Text] [Related]
2. Treatment with Granulocyte-Macrophage Colony-Stimulating Factor Reduces Viral Titers in the Brains of West Nile Virus-Infected Mice and Improves Survival.
Stonedahl S; Leser JS; Clarke P; Potter H; Boyd TD; Tyler KL
J Virol; 2023 Mar; 97(3):e0180522. PubMed ID: 36802227
[TBL] [Abstract][Full Text] [Related]
3. Recruiting the innate immune system with GM-CSF to fight viral diseases, including West Nile Virus encephalitis and COVID-19.
Potter H; Boyd TD; Clarke P; Pelak VS; Tyler KL
F1000Res; 2020; 9():345. PubMed ID: 32704352
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimer's disease.
Potter H; Woodcock JH; Boyd TD; Coughlan CM; O'Shaughnessy JR; Borges MT; Thaker AA; Raj BA; Adamszuk K; Scott D; Adame V; Anton P; Chial HJ; Gray H; Daniels J; Stocker ME; Sillau SH
Alzheimers Dement (N Y); 2021; 7(1):e12158. PubMed ID: 33778150
[TBL] [Abstract][Full Text] [Related]
5. Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?
Lazarus HM; Ragsdale CE; Gale RP; Lyman GH
Front Immunol; 2021; 12():706186. PubMed ID: 34484202
[TBL] [Abstract][Full Text] [Related]
6. Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial.
Bosteels C; Maes B; Van Damme K; De Leeuw E; Declercq J; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):491. PubMed ID: 32503663
[TBL] [Abstract][Full Text] [Related]
7. Sargramostim (GM-CSF) for induction of remission in Crohn's disease.
Roth L; Macdonald JK; McDonald JW; Chande N
Cochrane Database Syst Rev; 2011 Nov; (11):CD008538. PubMed ID: 22071853
[TBL] [Abstract][Full Text] [Related]
8. Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1-42 and suppresses microglial activity in a transgenic mouse model of Alzheimer's disease.
Manczak M; Mao P; Nakamura K; Bebbington C; Park B; Reddy PH
Hum Mol Genet; 2009 Oct; 18(20):3876-93. PubMed ID: 19617638
[TBL] [Abstract][Full Text] [Related]
9. Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: effect on infections, CD4 cell counts and HIV suppression. Leukine/HIV Study Group.
Angel JB; High K; Rhame F; Brand D; Whitmore JB; Agosti JM; Gilbert MJ; Deresinski S
AIDS; 2000 Mar; 14(4):387-95. PubMed ID: 10770541
[TBL] [Abstract][Full Text] [Related]
10. The influence of macrophage growth factors on Theiler's Murine Encephalomyelitis Virus (TMEV) infection and activation of macrophages.
Schneider KM; Watson NB; Minchenberg SB; Massa PT
Cytokine; 2018 Feb; 102():83-93. PubMed ID: 28800924
[TBL] [Abstract][Full Text] [Related]
11. Blocking the human common beta subunit of the GM-CSF, IL-5 and IL-3 receptors markedly reduces hyperinflammation in ARDS models.
Wang H; Tumes DJ; Hercus TR; Yip KH; Aloe C; Vlahos R; Lopez AF; Wilson N; Owczarek CM; Bozinovski S
Cell Death Dis; 2022 Feb; 13(2):137. PubMed ID: 35145069
[TBL] [Abstract][Full Text] [Related]
12. Granulocyte macrophage colony-stimulating factor receptor α expression and its targeting in antigen-induced arthritis and inflammation.
Cook AD; Louis C; Robinson MJ; Saleh R; Sleeman MA; Hamilton JA
Arthritis Res Ther; 2016 Dec; 18(1):287. PubMed ID: 27908288
[TBL] [Abstract][Full Text] [Related]
13. Targeting granulocyte-macrophage colony-stimulating factor in epithelial and vascular remodeling in experimental eosinophilic esophagitis.
McNamee EN; Biette KA; Hammer J; Harris R; Miyazawa H; Lee JJ; Furuta GT; Masterson JC
Allergy; 2017 Aug; 72(8):1232-1242. PubMed ID: 27926989
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in COVID-19 patients: a meta-analysis.
Xi AR; Luo YJ; Guan JT; Wang WJ; Xu ZH
Inflammopharmacology; 2023 Feb; 31(1):275-285. PubMed ID: 36445552
[TBL] [Abstract][Full Text] [Related]
15. Cytokine refacing effect reduces granulocyte macrophage colony-stimulating factor susceptibility to antibody neutralization.
Heinzelman P; Carlson SJ; Cox GN
Protein Eng Des Sel; 2015 Oct; 28(10):461-6. PubMed ID: 25855658
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis.
Bo L; Wang F; Zhu J; Li J; Deng X
Crit Care; 2011; 15(1):R58. PubMed ID: 21310070
[TBL] [Abstract][Full Text] [Related]
17. Loss of GM-CSF-dependent instruction of alveolar macrophages in COVID-19 provides a rationale for inhaled GM-CSF treatment.
Bosteels C; Van Damme KFA; De Leeuw E; Declercq J; Maes B; Bosteels V; Hoste L; Naesens L; Debeuf N; Deckers J; Cole B; Pardons M; Weiskopf D; Sette A; Weygaerde YV; Malfait T; Vandecasteele SJ; Demedts IK; Slabbynck H; Allard S; Depuydt P; Van Braeckel E; De Clercq J; Martens L; Dupont S; Seurinck R; Vandamme N; Haerynck F; Roychowdhury DF; Vandekerckhove L; Guilliams M; Tavernier SJ; Lambrecht BN
Cell Rep Med; 2022 Dec; 3(12):100833. PubMed ID: 36459994
[TBL] [Abstract][Full Text] [Related]
18. Innate immune responses to LPS in mouse lung are suppressed and reversed by neutralization of GM-CSF via repression of TLR-4.
Bozinovski S; Jones J; Beavitt SJ; Cook AD; Hamilton JA; Anderson GP
Am J Physiol Lung Cell Mol Physiol; 2004 Apr; 286(4):L877-85. PubMed ID: 14617520
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Mavrilimumab in Viral Infections Including SARS-CoV-2 Infection - A Brief Review.
Bhatt K; Garimella R; Taugir R; Mehta I; Jamal M; Vijayan R; Offor R; Nwankwo K; Arif U; Waheed K; Kumari P; Lathiya M; Michel G; Pandya N; Halpern J; Nasir H; Sanchez-Gonzalez MA
Infect Chemother; 2021 Mar; 53(1):1-12. PubMed ID: 34409778
[TBL] [Abstract][Full Text] [Related]
20. G-CSF and GM-CSF for treating or preventing neonatal infections.
Carr R; Modi N; Doré C
Cochrane Database Syst Rev; 2003; 2003(3):CD003066. PubMed ID: 12917944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
